Triple meeting – the point of turning to TPX-0022
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Triple meeting – Mirati gets an edge over Amgen
Mirati’s Kras inhibitor looks better than Amgen’s on efficacy, but toxicity worries prevent a knockout punch.
US panel puts the spotlight on pivotal Covid vaccine readouts
Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
Bayer faces an uphill fight with finerenone
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Aptinyx data reveal statistical trauma
An attempt to abrogate the placebo response does not seem to have gone as planned.
Small Galapagos setback prompts a bigger loss of sentiment
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
